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Abstract
Introduction: Apoptosis can influence both adipose tissue mass and its distribution. The suprafamily of tumour necrosis factor (TNF)
receptors stimulate apoptosis. The aim of the study was to assess serum concentrations of tumour necrosis factor alpha (TNF-a), TNF
soluble receptors (sTNFRs) and FAS in obese subjects and to examine the changes in these parameters after weight loss.
Material and methods: The study group consisted of 23 obese women without additional disease aged 36.6 ± 10.9 years. These were
examined before and after three-month weight reduction treatment consisting of a diet of 1000 kcal/day and physical exercise. The control
group comprised 17 lean healthy women aged 40.3 ± 5.5 years. Blood samples were taken in the morning after an overnight fast. Serum
concentrations of TNF-a, sTNFRs and FAS were measured by enzyme linked immunosorbent assay (ELISA). Serum concentrations of
insulin were measured by RIA. Serum concentrations of glucose, total cholesterol, HDL cholesterol and triglycerides were measured by an
enzymatic procedure.
Results: The mean weight loss over the three-month treatment was 11.4 ± 3.1 kg. Following weight loss, serum TNF-a concentrations
decreased significantly (7.3 ± 3.0 vs. 5.4 ± 1.6 pg/ml; p < 0.005) and concentrations of sTNFRs increased significantly (1222.6 ± 211.8 vs.
1325.6 ± 261.6 pg/ml; p < 0.05 and 1881.5 ± 337.2 vs. 2057.4 ± 358.7 pg/ml; p < 0.05 respectively). However, no changes in serum concen-
trations of FAS were observed after weight loss.
Conclusion: We observed increased serum concentrations of TNF-a but not of FAS in obese women. The concentrations of TNF decreased
and those of sTNFRs increased after weight loss. However, the weight reduction therapy did not change serum concentrations of FAS.
(Pol J Endocrinol 2008; 59 (1): 18–22)
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Streszczenie
Wstęp: Proces apoptozy może wpływać zarówno na masę, jak i na rozmieszczenie tkanki tłuszczowej. Nadrodzina receptorów dla czyn-
nika martwicy nowotworów (TNF, tumour necrosis factor) stymuluje apoptozę. Celem pracy była ocena stężeń TNF-a, rozpuszczalnych
form receptorów dla TNF oraz FAS w surowicy otyłych kobiet oraz ich zmiany po zmniejszeniu masy ciała.
Materiał i metody: Grupę 23 otyłych kobiet bez chorób towarzyszących (średni wiek 36,6 ± 10,9 lat) poddano 3-miesięcznej kuracji
odchudzającej składającej się z diety 1000 kcal oraz aktywności fizycznej. Grupę kontrolną stanowiło 17 zdrowych kobiet z prawidłową
masą ciała (średnia wieku 40,3 ± 5,5 roku). Próbkę krwi pobierano na czczo w godzinach porannych. Stężenia TNF-a, receptorów dla TNF
oraz FAS oznaczono metodą ELISA. Stężenie insuliny oznaczono przy użyciu metody RIA. Stężenia glukozy, cholesterolu całkowitego,
cholesterolu frakcji HDL oraz triglicerydów oznaczono metodą enzymatyczną.
Wyniki: Średnie zmniejszenie masy ciała w trakcie 3-miesięcznej kuracji odchudzającej wyniosło 11,4 ± 3,1 kg. Stężenie TNF-a uległo
obniżeniu (7,3 ± 3,0 vs. 5,4 ± 1,6 pg/ml; p < 0,005), stężenie sTNFRs uległo podwyższeniu (odpowiednio: 1222,6 ± 211,8 vs. 1325,6 ± 261,6
pg/ml; p < 0,05 oraz 1881,5 ± 337,2 vs. 2057,4 ± 358,7 pg/ml; p < 0,05). Nie zaobserwowano zmian w stężeniu FAS po zmniejszeniu masy
ciała.
Wnioski: U otyłych kobiet zaobserwowano wyższe stężenie TNF-a w osoczu w porównaniu z osobami z prawidłową masą ciała, nie
zaobserwowano różnic w stężeniu FAS. Stężenie TNF uległo obniżeniu, a stężenie sTNFRs wzrosło po zmniejszeniu masy ciała. Redukcja
masy ciała nie spowodowała zmian w stężeniu FAS. (Endokrynol Pol 2008; 59 (1): 18–22)
Słowa kluczowe: otyłość, FAS, TNF-a, sTNFRs
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Apoptosis can influence both adipose tissue mass and
its distribution. The suprafamily of TNF receptors sti-
mulate apoptosis.
Tumour necrosis factor a (TNF-a) is a proinflamma-
tory cytokine produced by a wide range of cells,
amongst which are fat cells [1]. The action of TNF-a in-
cludes modulation of lipid metabolism and insulin re-
sistance, especially by defects in insulin-stimulated glu-
cose disposal [2]. It decreases the activity of lipoprotein
lipase, and increases hormone-sensitive lipase, thus pre-
venting lipid accumulation [3]. TNF-a could be a local
regulator of fat cell size, and its overproduction in adi-
pocytes of obese animals may limit adipocyte size en-
largement [4].
Tumour necrosis factor a acts by its two membrane
and soluble receptors (sTNFRs). Of these, sTNFR1 do-
minates in the actions of TNF-a, such as apoptosis, cell
differentiation and proliferation, cytotoxicity and insu-
lin resistance, while sTNFR2 participates in the stimula-
tion of cytokine production, cytotoxicity of T cells and
insulin resistance [5].
FAS (CD95/APO-1) is a member of the tumour ne-
crosis factor receptor family (TNFR) [6]. FAS is a 45-kDa
type I membrane protein expressed constitutively in va-
rious tissues, such as the liver, lung, kidney, spleen,
lymph nodes and ovary [7]. FAS and its specific ligand
(FasL) have been implicated in the control of inflam-
mation, response to infection, neoplasia, immune
response and death of parenchymal cells in several
organs [8, 9]. A defect of the FAS system can limit lym-
phocyte apoptosis and lead to autoimmunity and lym-
phoproliferation [10].
 Many studies have shown that TNF-a and TNF re-
ceptors are expressed in fat cells and their production
is increased in obesity [11, 12]. Our previous results [13,
14] and those of other studies [15, 16] have shown in-
creased serum levels of TNF-a and sTNFRs in obese
patients in comparison to lean subjects. However, it is
still unknown how far obesity influences serum con-
centration of FAS. The aim of the study therefore was
to assess serum concentrations of TNF-a, sTNFRs and
FAS in obese subjects and to examine changes to the
cytokine and its receptors after weight loss.
Material and methods
The study was carried out on 23 obese women weighing
97.5 ± 16.6 kg, aged 36.6 ± 10.9 years and with a body
mass index (BMI) of 36.6 ± 5.6 kg/m2. All subjects were
diagnosed as having simple obesity with no concomi-
tant diseases and without pharmacological treatment.
The obese patients were stable in weight at the time of
enrolment and patients with a sudden loss or increase
in weight were excluded from the study. Each had
a history of obesity lasting for some years. All the pa-
tients had serum concentrations of glucose and insulin
within the reference range.
The control group consisted of 17 apparently heal-
thy women aged 40.3 ± 5.5 years, who were age-mat-
ched to the study subjects. Their weight and BMI were
60.4 ± 6.3 kg and 22.6 ± 1.8 kg/m2 respectively.
The exclusion criteria included evidence of present
or recent (during the preceding three months) infectio-
us disease, fever or drug therapy.
The study was approved by the local committee for
ethics. All the subjects had given their informed con-
sent to the study.
All the obese patients participated in a three-month we-
ight reduction programme with the following components:
— group instruction at two weekly intervals in beha-
vioural and dietary methods of weight control;
— a 1000–1200 kcal/day balanced diet with 50–60% of
carbohydrates, less than 30% of fat and 10–20% of
protein;
— physical exercise (30–40 minutes every day of run-
ning, swimming or cycling).
The measurements were performed at the baseline
(both study and control groups) and after the three-
-month programme (the study group only). Body we-
ight and height were measured and BMI was calcula-
ted. Body composition was assessed by impedance ana-
lysis using the Bodystat analyser.
Determination of FAS, TNF-a and sTNFRs in the
blood serum was carried out by enzyme-linked immu-
nosorbent assay (ELISA). After an overnight fast 6–8 ml
samples of venous blood were collected from each sub-
ject between 8 a.m. and 9 a.m. in the morning. Following
clot formation, the samples were centrifuged (1000 g)
at room temperature for 10 minutes. The serum
obtained was drawn into plastic vials and stored at
–80°C until the time of the assay.
The Phoenix Pharmaceuticals Inc. kit was used for
the FAS assay. The sensitivity of this was less than
20.0 pg/ml. The intra-assay and inter-assay coefficients
of variation were < 4.6%, and < 2.9% respectively.
Tumour necrosis factor-a and the soluble forms of
both TNF-a receptors sTNFR1 and sTNFR2 were me-
asured using a commercially available highly sensitive
ELISA kit (Genzyme Diagnostics, Cambridge, USA).
The minimum detectable concentration of TNF-a is
typically less than 0.18 pg/ml. The mean intra-assay co-
efficient of variance was 14.4%, range 8.7–14.8%, and
the mean inter-assay coefficient of variance was 18.7%,
range 16.1–22.6%. The minimum detectable concentra-
tion of sTNFR1 is typically less than 3.0 pg/ml. The mean
intra-assay coefficient of variance was 2.9%, range
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Table II. Plasma glucose, insulin and lipids
Tabela II. Stężenia glukozy, insuliny i lipidów w osoczu
Obese Control
Before After
Glucose [mg/dl] 89.7±8.5 94.4±13.1 86.4±10.8
Insulin [mIU/ml]  16.8±7.9 12.6±5.6* 7.8±3.4###
Total cholesterol [mg/dl] 201.0±34.5 198.6±31.6 205.1±25.2
HDL cholesterol [mg/dl] 51.9±9.0 55.7±8.2* 55.3±7.4#
LDL cholesterol [mg/dl] 130.0±35.2 129.76±30.1 134.0±28.3
Triglycerides [mg/dl] 96.6±36.3 89.0±26.1 91.9±45.4
* — p < 0.005 obese before vs. after; # — p < 0.05; ### — p < 0.001 obese before treatment vs. control
2.7–6.9%, and the mean inter-assay coefficient of varian-
ce was 3.7%, range 5.8–8.8%. The minimum detectable
concentration of sTNFR2 is typically less than 1.0 pg/ml.
The mean intra-assay coefficient of variance was 2.5%,
range 1.6–2.5%, and the mean inter-assay coefficient of
variance was 3.5%, range 3.5–5.1%.
Plasma glucose, total cholesterol, HDL cholesterol and
triglycerides were determined by an enzymatic procedu-
re using a commercially available test kit (Cormay). LDL
cholesterol was calculated using the Friedwald formula.
Insulin was determined by radioimmunoassay (DPC
Diagnostic Products Corporation, Los Angeles, USA)
with a lower limit of sensitivity of 1.2 mIU/ml and
intra-assay and inter-assay coefficients of variation of
5.2% and 5.8% respectively.
Statistical analysis
All text and table values are expressed as means ± SD.
The results were examined with the use of ANOVA with
the Newman-Keuls correction. Wilcoxon rank-sum tests
(for continuous and ordered variables) and Fisher’s
exact tests (for discrete variables) were used to compare
baseline and post-follow-up clinical/laboratory characte-
ristics. Stepwise multivariate analysis was performed with
serum levels of FAS, DFAS, TNF-a and DTNF-a as the
dependent variables. A value of p < 0.05 was conside-
red statistically significant.
Results
The characteristics of patients and the effects of treat-
ment are presented in Table I.
Mean weight loss was 11.4 ± 3.0 kg. BMI decreased
from 36.6 ± 5.6 at the baseline to 32.3 ± 5.2 following
treatment. Some significant differences in body com-
position were also found. The body weight reduction
treatment led to a significant decrease in body fat (ab-
solute and percentage p < 0.005 and p < 0.05 respecti-
vely), accompanied by an increase in fat-free mass per-
centage p < 0.05.
Serum concentrations of insulin decreased signifi-
cantly and serum concentrations of HDL cholesterol
increased significantly after weight loss (p < 0.005;
p < 0.005 respectively) (Tab. II).
There were no differences between plasma FAS
concentrations in obese patients and controls. In obe-
Table I. Patient characteristics and the effect of weight-reducing treatment
Tabela I. Charakterystyka pacjentów i efekty kuracji odchudzającej
Obese Control
Before After
Body mass (kg)  97.5±16.6 86.1±15.2 ***  60.4±6.3 ###
BMI [kg/m2] 36.6±5.6 32.3±5.2 *** 22.6±1.8 ###
Fat-free mass (kg)  54.7±5.3 52.2±5.6 45.4±5.0 ###
Fat-free mass (%)  56.3±9.0 60.5±5.9 ** 75.2±3.6 ###
Body f at (kg)  43.8±14.9 35.5±10.2 *** 15.0±3.2 ###
Body f at (%)  43.4±9.1 40.1±6.2 * 24.8±3.6 ###
* — p < 0.05; ** — p < 0.005; *** — p < 0.0005 obese before vs. after; ### — p < 0.001 obese before treatment vs. control
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se subjects FAS levels did not change following we-
ight loss (Tab. III).
The TNF-a determination showed significantly hi-
gher TNF levels in the obese subjects than in the con-
trols (p < 0.001). Additionally, TNF-a levels decreased
significantly after weight loss (p < 0.005) (Tab. III).
There were no differences between the obese pa-
tients and the controls in plasma sTNFRs concentrations
(Tab. III). However, in the obese subjects sTNFRs levels
increased significantly following weight loss (p < 0.05).
 There was a positive correlation between BMI and
FAS levels and between serum concentrations of FAS
and TNF-a before treatment (Tab. IV).
 No correlations were found between serum FAS,
TNF-a and sTNFRs concentrations and age, body mass,
body fat, glucose or insulin before and after weight re-
duction (Tab. V).
 There were significant positive correlations betwe-
en D body mass and D serum concentrations of insulin
(r = 0.43; p < 0.05) and between D serum concentra-
tions of insulin and D serum concentrations of sTNFR1
(r = 0.49; p < 0.05).
An analysis of the remaining regression coefficients
did not reveal any significant differences.
Discussion
The present study evaluates baseline and post-weight loss
concentrations of FAS and TNF-a, which seem to be po-
tent factors of apoptosis. As described above, FAS is a mem-
ber of the tumour necrosis factor receptor family [6].
 The TNF-a may exert a catabolic effect and could
represent a form of local adipostat [4]. According to some
studies, increased TNF-a production is restricted to adi-
pose deposits [12]. Serum concentrations of some mem-
bers of this family, such as TNF-a, sTNFR1 and sTNFR2
are increased in cases of obesity [13, 14], and it seems
that this may be a counter-regulatory mechanism pre-
venting further weight gain. Our recent studies [13, 17]
revealed that weight reduction changes serum concen-
trations of TNF-a, sTNFR1 and sTNFR2. We observed
that serum concentrations of TNF-a decreased and its
soluble receptors increased after weight loss. However,
there is so far a lack of data regarding serum concentra-
tions of FAS in obesity and the influence of weight re-
duction on serum concentration of FAS.
 We thus speculate that baseline FAS secretion in
long-lasting obesity may represent a physiological ada-
ptation to a positive energy balance. In support of our
notion is the fact that the weight of our obese patients
was stable at the time of enrolment, both patients with
sudden weight loss and those with sudden weight gain
having been excluded from the study. Further results
of studies obtained during weight loss and weight gain
will clarify the role of FAS in the development and pre-
vention of obesity.
In the present study, as in our previous studies [12–
–14], we observed increased serum concentrations of
Table III. Serum concentrations of TNF-a, TNF receptors and FAS
Tabela III. Stężenie TNF-a, receptorów TNF i FAS w surowicy
Before After Control
TNF-a [pg/ml] 7.3±3.0  5.4±1.6**  2.3±0.5###
sTNFR1 [pg/ml] 1222.6±211.8 1325.6±261.6* 1144.0±102.0
sTNFR2 [pg/ml] 1881.5±337.2 2057.4±358.7* 1791.0±504.2
FAS [pg/ml] 8904.2±1777.2 8434.3±2122.6 8274.6±1459.9
* — p < 0.05; ** — p < 0.005 obese before vs. after; # — p < 0.05; ### — p < 0.001 obese before treatment vs. control
Table IV. Correlations between study parameters before treatment
Tabela IV. Korelacje między badanymi parametrami przed terapią
Total cholesterol LDL cholesterol HDL cholesterol Triglycerides FAS TNF
Age 0.47* 0.46* 0.44*
Body mass 0.49* 0.52*
BMI 0.56** 0.61* –0.45* 0.43*
FFM% –0.52* –0.51* –0.43*
FAS 0.62** 0.65*** 0.43* 0.43*
 * — p < 0.05; ** — p < 0.01
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TNF-a in obese subjects when compared to lean con-
trols. However, our study no revealed increased serum
concentration of FAS in obese women. Weight loss de-
creased serum concentration of TNF-a but not FAS. This
is interesting because we observed a positive correla-
tion between BMI and FAS levels and between serum
concentrations of FAS and TNF-a before treatment. It
seems that a decrease in serum concentrations of
TNF-a after weight loss may be a result of both a decre-
ase in fat deposit and an increase in serum concentra-
tions of sTNFR1 and sTNFR2. This is in accordance with
results obtained by Hotamisgli et al. [1], who reported
a decrease in TNF-a mRNA expression in fat tissue after
body weight reduction.
It seems that the cause of lack of change in the con-
centration of FAS after weight reduction may be its pro-
duction by tissues other than adipose tissue and a me-
chanism of action of FAS in apoptosis other than the
action of TNF-a. Thomas et al. [18] revealed that the
C-terminal tails of TNF, the apoptosis-inducing ligand
(TRAIL) and FAS receptors have opposing functions
in FAS-associated death domain (FADD) recruitment
and can regulate agonist-specific mechanisms of
receptor activation. Further studies are necessary to
clarify the role of FAS in apoptosis in obesity and the
pathophysiology of obesity, because it seems that the
decrease in serum concentrations of TNF-a and the
lack of change in the serum concentration of FAS may
be two independent mechanisms preventing further
weight loss.
Conclusions
 We observed increased serum concentrations of tumo-
ur necrosis factor alpha but not of FAS in obese wo-
men. The concentrations of tumour necrosis factor
alpha decreased and tumour necrosis factor soluble
receptors increased after weight loss. However, the we-
Table V. Correlations between study parameters after treatment
Tabela V. Korelacje między badanymi parametrami po terapii
Total cholesterol LDL cholesterol Triglycerides Glucose STNFR2 FAS TNF
Age 0.43* 0.48* 0.48*
FFM% –0.43* –0.53* –0.45* 0.48*
sTNFR1 –0.45* –0.44* 0.43* 0.43*
sTNFR2 –0.47* –0.45*
* — p < 0.05; ** — p < 0.01
ight reduction therapy did not change serum concentra-
tion of FAS.
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